Patents by Inventor Layton H. Smith
Layton H. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230339872Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: ApplicationFiled: April 28, 2023Publication date: October 26, 2023Inventors: Layton H. SMITH, Anthony B. PINKERTON, Paul HERSHBERGER, Patrick MALONEY, Danielle MCANALLY
-
Patent number: 11673873Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: GrantFiled: May 7, 2020Date of Patent: June 13, 2023Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
-
Publication number: 20230037225Abstract: Provided herein are agonists of the apelin receptor of Formula (I): for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: ApplicationFiled: May 12, 2022Publication date: February 2, 2023Inventors: Layton H. SMITH, Anthony B. PINKERTON, Paul HERSHBERGER, Patrick MALONEY, Danielle MCANALLY
-
Publication number: 20220402908Abstract: Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthesis is also described. Also provided are method of treating a disease or condition (such as, cancer) mediated by CXCR6/CXCL16 signaling pathway in a mammal.Type: ApplicationFiled: July 7, 2020Publication date: December 22, 2022Inventors: Satyamaheshwar PEDDIBHOTLA, Paul M. HERSHBERGER, Richard Jason KIRBY, Siobhan MALANY, Layton H. SMITH, Patrick R. MALONEY, Hampton SESSIONS, Daniela DIVLIANSKA, Anthony B. PINKERTON
-
Patent number: 11345705Abstract: Provided herein are agonists of the apelin receptor of Formula (I): for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: GrantFiled: August 8, 2018Date of Patent: May 31, 2022Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
-
Publication number: 20220144784Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: ApplicationFiled: October 20, 2021Publication date: May 12, 2022Inventors: Takuya IKEDA, Yoshiyuki KOBAYASHI, Naoki MIYOSHI, Osamu SUZUKI, Takahiro NAGAYAMA, Takashi TSUJI, Layton H. SMITH, Anthony B. PINKERTON
-
Publication number: 20210363142Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).Type: ApplicationFiled: March 22, 2021Publication date: November 25, 2021Inventors: Anthony B. PINKERTON, Layton H. SMITH
-
Patent number: 11155525Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: GrantFiled: April 20, 2020Date of Patent: October 26, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Takuya Ikeda, Yoshiyuki Kobayashi, Naoki Miyoshi, Osamu Suzuki, Takahiro Nagayama, Takashi Tsuji, Layton H. Smith, Anthony B. Pinkerton
-
Patent number: 10988475Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).Type: GrantFiled: January 14, 2020Date of Patent: April 27, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Layton H. Smith
-
Publication number: 20210040098Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: ApplicationFiled: August 8, 2018Publication date: February 11, 2021Inventors: Layton H. SMITH, Anthony B. PINKERTON, Paul HERSHBERGER, Patrick MALONEY, Danielle MCANALLY
-
Publication number: 20200392092Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: ApplicationFiled: May 7, 2020Publication date: December 17, 2020Inventors: Layton H. SMITH, Anthony B. PINKERTON, Paul HERSHBERGER, Patrick MALONEY, Danielle MCANALLY
-
Publication number: 20200354355Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).Type: ApplicationFiled: January 14, 2020Publication date: November 12, 2020Inventors: Anthony B. PINKERTON, Layton H. SMITH
-
Publication number: 20200347022Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: ApplicationFiled: April 20, 2020Publication date: November 5, 2020Inventors: Takuya IKEDA, Yoshiyuki KOBAYASHI, Naoki MIYOSHI, Osamu SUZUKI, Takahiro NAGAYAMA, Takashi TSUJI, Layton H. SMITH, Anthony B. PINKERTON
-
Patent number: 10647689Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: GrantFiled: April 28, 2016Date of Patent: May 12, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
-
Patent number: 10626096Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: GrantFiled: November 21, 2016Date of Patent: April 21, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Takuya Ikeda, Yoshiyuki Kobayashi, Naoki Miyoshi, Osamu Suzuki, Takahiro Nagayama, Takashi Tsuji, Layton H. Smith, Anthony B. Pinkerton
-
Patent number: 10570128Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).Type: GrantFiled: May 27, 2015Date of Patent: February 25, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Layton H. Smith
-
Publication number: 20180282289Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: ApplicationFiled: November 21, 2016Publication date: October 4, 2018Inventors: Takuya IKEDA, Yoshiyuki KOBAYASHI, Naoki MIYOSHI, Osamu SUZUKI, Takahiro NAGAYAMA, Takashi TSUJI, Layton H. SMITH, Anthony B. PINKERTON
-
Publication number: 20180118698Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: ApplicationFiled: April 28, 2016Publication date: May 3, 2018Inventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
-
Publication number: 20170197958Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).Type: ApplicationFiled: May 27, 2015Publication date: July 13, 2017Inventors: Anthony B. Pinkerton, Layton H. Smith